Form 4: United Therapeutics Director Jan Malcolm Reports Stock and Options Award

Director Jan Malcolm reports the acquisition of stock options and restricted stock units in United Therapeutics Corporation.

Summary

• On July 25, 2024, Jan Malcolm, a director of United Therapeutics Corporation, reported the acquisition of 1,440 stock options and 590 restricted stock units (RSUs) as part of an annual non-employee director award.
• The stock options have an exercise price of $336.37 and vest on July 25, 2025, expiring on July 25, 2034.
• The RSUs also vest on July 25, 2025, and each RSU represents the right to receive one share of United Therapeutics Corporation common stock.
• Following the reported transaction, Malcolm directly owns 1,440 derivative securities and 590 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices that align director interests with shareholder value. There are no indications of negative events or concerns.

Positives

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders, incentivizing performance and value creation.
• The vesting period of one year encourages the director's continued service and commitment to the company.

Industry Context

This filing is a routine disclosure related to executive compensation practices, which are common in publicly traded companies to align management and shareholder interests. The grant of stock options and RSUs is a typical component of compensation packages for directors and executives in the biotechnology industry.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for compensating board members in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation to incentivize their directors.
• The vesting schedules and terms of these grants are generally in line with industry norms, promoting long-term alignment with shareholder value.

Stakeholder Impact

• The grant of stock options and RSUs can positively impact shareholders by aligning the director's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates